Literature DB >> 22833045

In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder.

Edna Grünblatt1, Jasmin Bartl, Zoya Marinova, Susanne Walitza.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in children and adolescents, with up to 5 % affected worldwide. Twin and family studies on ADHD show its high familiality with heritability estimated around 70 %, but, to date, no specific polymorphism or gene was found to be specifically affected. Psychostimulants (amphetamine, methylphenidate) and non-psychostimulants (atomoxetine) are used successfully in ADHD therapy, but many of their mechanisms of action and their adverse effects are not yet fully understood. Therefore, both genetic findings and therapeutic interventions should be further investigated. One easy platform for such studies is in vitro analyses, which encompass neuronal cell culture studies, transfections of genetic constructs, binding and electrophysiology analyses. In this review, different methods will be referred in particular to ADHD findings, and new techniques will be mentioned for future studies of drug or genetic effects in vitro.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22833045     DOI: 10.1007/s00702-012-0869-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  61 in total

1.  Microscopy and its focal switch.

Authors:  Stefan W Hell
Journal:  Nat Methods       Date:  2009-01       Impact factor: 28.547

Review 2.  [Differences in neuronal toxicity and its molecular mechanisms between methamphetamine and methylphenidate].

Authors:  Minoru Narita; Megumi Asato; Keiko Shindo; Naoko Kuzumaki; Tsutomu Suzuki
Journal:  Nihon Shinkei Seishin Yakurigaku Zasshi       Date:  2009-06

3.  Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence.

Authors:  Mayumi Miyatake; Minoru Narita; Masahiro Shibasaki; Atsushi Nakamura; Tsutomu Suzuki
Journal:  Eur J Neurosci       Date:  2005-09       Impact factor: 3.386

4.  Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD.

Authors:  Zsofia Nemoda; Nora Angyal; Zsanett Tarnok; Julia Gadoros; Maria Sasvari-Szekely
Journal:  Neuropharmacology       Date:  2009-09-04       Impact factor: 5.250

5.  Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse.

Authors:  Minoru Narita; Mayumi Miyatake; Michiko Narita; Masahiro Shibasaki; Keiko Shindo; Atsushi Nakamura; Naoko Kuzumaki; Yasuyuki Nagumo; Tsutomu Suzuki
Journal:  Neuropsychopharmacology       Date:  2006-01-11       Impact factor: 7.853

6.  Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

Authors:  U Mayer; E Wagenaar; B Dorobek; J H Beijnen; P Borst; A H Schinkel
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

7.  The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor.

Authors:  J S Markowitz; C L DeVane; S Ramamoorthy; Hao-Jie Zhu
Journal:  Pharmazie       Date:  2009-02       Impact factor: 1.267

8.  Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.

Authors:  Hao-Jie Zhu; Kennerly S Patrick; Hong-Jie Yuan; Jun-Sheng Wang; Jennifer L Donovan; C Lindsay DeVane; Robert Malcolm; Julie A Johnson; Geri L Youngblood; Douglas H Sweet; Taimour Y Langaee; John S Markowitz
Journal:  Am J Hum Genet       Date:  2008-05-15       Impact factor: 11.025

Review 9.  Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?

Authors:  John S Markowitz; Kennerly S Patrick
Journal:  J Clin Psychopharmacol       Date:  2008-06       Impact factor: 3.153

10.  European guidelines on managing adverse effects of medication for ADHD.

Authors:  J Graham; T Banaschewski; J Buitelaar; D Coghill; M Danckaerts; R W Dittmann; M Döpfner; R Hamilton; C Hollis; M Holtmann; M Hulpke-Wette; M Lecendreux; E Rosenthal; A Rothenberger; P Santosh; J Sergeant; E Simonoff; E Sonuga-Barke; I C K Wong; A Zuddas; H-C Steinhausen; E Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-11-03       Impact factor: 4.785

View more
  3 in total

1.  Evidence That Methylphenidate Treatment Evokes Anxiety-Like Behavior Through Glucose Hypometabolism and Disruption of the Orbitofrontal Cortex Metabolic Networks.

Authors:  Felipe Schmitz; Josiane S Silveira; Gianina T Venturin; Samuel Greggio; Guilherme Schu; Eduardo R Zimmer; Jaderson Costa Da Costa; Angela T S Wyse
Journal:  Neurotox Res       Date:  2021-11-19       Impact factor: 3.911

Review 2.  Challenges in understanding psychiatric disorders and developing therapeutics: a role for zebrafish.

Authors:  Jasmine M McCammon; Hazel Sive
Journal:  Dis Model Mech       Date:  2015-07-01       Impact factor: 5.758

Review 3.  Mental health dished up-the use of iPSC models in neuropsychiatric research.

Authors:  Rhiannon V McNeill; Georg C Ziegler; Franziska Radtke; Matthias Nieberler; Klaus-Peter Lesch; Sarah Kittel-Schneider
Journal:  J Neural Transm (Vienna)       Date:  2020-05-07       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.